Special Issues

Hormone Receptors in Human Malignancies

Submission Deadline: 31 January 2025 View: 62 Submit to Special Issue

Guest Editors

Hiroshi Miyamoto, Director of Genitourinary Pathology at University of Rochester Medical Center, Professor of Pathology & Laboratory Medicine and Urology, University of Rochester School of Medicine and Dentistry, Rochester, NY 14642, United States. E-mail: Hiroshi_Miyamoto@URMC.Rochester.edu

Shuyuan Yeh, Department of Urology, University of Rochester Medical Center, Rochester, NY 14642, United States. E-mail: shuyuan_yeh@urmc.rochester.edu

Summary

Hormone receptors are two classes of proteins, those for peptide hormones and steroid hormones, and can act as transcription factors that regulate the expression of specific genes, including those involving critical biological functions, via binding of their cognate ligands. Meanwhile, a growing body of evidence suggests that hormone receptors play an important role in the development and progression of various types of malignancies, although their exact functions are not fully characterized. In particular, the roles of sex hormone receptors, such as androgen receptor and estrogen/progesterone receptors, have been extensively studied in prostate and breast cancers, respectively, and anti-hormone therapy has been widely used for these malignancies. The aim of this Special Issue is to provide an overview of current preclinical and clinical findings indicating the involvement of hormone receptor signals in not only prostate and breast cancers but also other malignancies that have not traditionally been considered as endocrine neoplasms, including, but not limited to, lung cancer, gastrointestinal cancer, liver cancer, endometrial cancer, ovarian cancer, and urothelial cancer of the bladder or upper urinary tract. Original research or review articles on signaling related to any hormone receptor in any human malignancy would be most welcome.


Keywords

Steroid hormone receptors; Peptide hormone receptors; Carcinogenesis; Cancer progression; Metastasis; Therapeutic resistance; Prognosis; Transactivation; Transrepression; Coactivators; Corepressors; Agonists; Antagonists

Share Link